Opus Genetics: regulation FD disclosure

What happened The filing says Opus Genetics, Inc. issued a press release on Oct 15, 2026 regarding the Company’s Oct 14, 2026 presentations at the Retina in Rio 2026 conference in Rio de Janeiro, Brazil. The presentations covered clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 and clinical data from the Company’s ongoing Phase 1/2/3 clinical trial of OPGx-LCA5.

Key details

• Press release issued on Oct 15, 2026 about presentations given on Oct 14, 2026 at Retina in Rio 2026.
• Presentations covered Cohort 1 clinical data for Phase 1/2 OPGx-BEST1 and clinical data from the ongoing Phase 1/2/3 OPGx-LCA5 trial.
• The company furnished related presentation materials in the 8-K filing.

Why it may matter This item was reported under Item 7.01, Regulation FD disclosure, which covers the Company’s press release and presentations that include clinical trial data. A filing does not show why the insider traded or why the company acted.